MarketCapExport financials
Alnylam Pharmaceuticals (ALNY)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Alnylam Pharmaceuticals Cash Flow 2025-2007 | ALNY
Brief cash flow overview of Alnylam Pharmaceuticals
Cash flows are assessed across five available annual periods spanning 2021 to 2025.
Operating cash flow recovered from negative territory and reached $524.1 million. Core operations returned to generating cash.
Positive operating cash flow appeared only 2 times out of five; a stable cash profile has not formed.
Cash from operations as a share of revenue increased from -76% to 14.1%, improving cash efficiency.
Receivables and inventory net of payables grew by $658.4 million, absorbing resources equal to about 17.7% of revenue.
Overall assessment
Alnylam Pharmaceuticals's cash flows present a mixed picture: positive periods coexist with weak conversion or high funding needs.
Annual Cash Flow Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
524 M | -8.31 M | 104 M | -541 M | -642 M | -615 M | -278 M | -563 M | -383 M | -308 M | - | - | -68.7 M | -116 M | -87.1 M | -84.3 M | -72.1 M | 65.5 M | - |
Depreciation & Amortization |
55.7 M | 56.7 M | 54.1 M | 44.5 M | 47.6 M | 34.8 M | 17.2 M | 15.2 M | 13.4 M | 15.1 M | 19 M | 11.9 M | 10.2 M | 9.04 M | 5.12 M | 4.94 M | 5.99 M | 5.73 M | - |
Accounts Payables |
116 M | 88.4 M | 55.5 M | 98.1 M | 73.4 M | 52 M | 49.9 M | 59.7 M | 28.4 M | 54.5 M | 16.8 M | 15.1 M | 5.9 M | 4.42 M | 5.8 M | 9.31 M | 12.5 M | - | - |
Accounts Receivables |
778 M | 103 M | 99.6 M | 32.3 M | 73.3 M | 33.5 M | 14.9 M | 18.8 M | 34 M | 23.3 M | 8.3 M | 39.9 M | 4.25 M | 104 K | 1.47 M | 3.45 M | 6.04 M | - | - |
Total Inventories |
82.7 M | 78.5 M | 89.1 M | 129 M | 86.4 M | 75.2 M | 56.3 M | 24.1 M | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Alnylam Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | 397 M | 218 M | 297 M | 128 M | -118 M | -94.7 M | 43.7 M | 124 M | -81.5 M | -29.8 M | 359 M | -59 M | -166 M | -132 M | -115 M | -123 M | -171 M | -150 M | -134 M | -122 M | -236 M | -123 M | -110 M | -135 M | -246 M | -196 M | -183 M | 289 M | -189 M | -150 M | -154 M | -103 M | -156 M | -103 M | -98.4 M | -181 M | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.4 M | -21.7 M | -23.6 M | -971 K | -68.9 M | 5.21 M | -21.7 M | -30.2 M | -25.2 M | -29 M | -26.6 M | -6.3 M | -20.4 M | -24 M | -39.9 M |
Depreciation & Amortization |
- | 27.5 M | 12.6 M | 13.8 M | 13.9 M | 14.4 M | 12.6 M | 14 M | 15 M | 13.5 M | 11 M | 13.3 M | 13.2 M | 14.1 M | 8.94 M | 10.6 M | 10.1 M | 9.46 M | 608 K | 11.8 M | 11.8 M | 12.6 M | 5.81 M | 8.57 M | 8.2 M | 7.61 M | 4.87 M | 4.04 M | 3.86 M | 3.84 M | 6.98 M | 405 K | 2.24 M | 3.18 M | 2.25 M | 3.59 M | 3.07 M | 3 M | -2.51 M | 3.5 M | 4.01 M | 4.6 M | -7.28 M | 5.27 M | 5.02 M | 3.69 M | -3.58 M | 3.12 M | 2.87 M | 2.6 M | -1.5 M | 2.76 M | 2.71 M | 2.13 M | -2.41 M | 2.28 M | 2.6 M | 2.12 M | 1.11 M | 1.26 M | 1.29 M | 1.34 M | - | 1.27 M | 2.38 M |
Accounts Payables |
135 M | 108 M | 116 M | 118 M | 102 M | 97.4 M | 88.4 M | 70.8 M | 74 M | 78.1 M | 55.5 M | 73.8 M | 59.7 M | 62.2 M | 98.1 M | 40.6 M | 52.4 M | 54.9 M | 73.4 M | 40 M | 53.1 M | 45.4 M | 52 M | 27.9 M | 26.1 M | 40.5 M | 49.9 M | 39.4 M | 71.2 M | 22.7 M | 59.7 M | 21.8 M | 12 M | 13.2 M | 28.4 M | 9.24 M | 23.2 M | 25.4 M | 54.5 M | 23.1 M | 12.8 M | 17.4 M | 16.8 M | 14.3 M | 15.7 M | 15.5 M | 15.1 M | 5.2 M | 6.17 M | 5.04 M | 5.9 M | 2.73 M | 4.53 M | 3.1 M | 4.42 M | 5.09 M | 5.52 M | 4.34 M | 5.8 M | 5.49 M | 7.95 M | 5.8 M | 9.31 M | 6.56 M | 10.4 M |
Accounts Receivables |
1.08 B | 913 M | 778 M | 965 M | 567 M | 418 M | 405 M | 354 M | 309 M | 321 M | 328 M | 325 M | 221 M | 219 M | 238 M | 185 M | 142 M | 157 M | 199 M | 141 M | 147 M | 111 M | 102 M | 79.1 M | 69.1 M | 75.6 M | 43 M | 48.1 M | 30.7 M | 33.8 M | 18.8 M | 3.36 M | 2.96 M | 50.8 M | 34 M | 14.6 M | 15.4 M | 19.5 M | 23.3 M | 15.1 M | 9.51 M | 8.81 M | 8.3 M | 8.13 M | 9.4 M | 10.1 M | 39.9 M | 384 K | 89 K | 164 K | 4.25 M | 609 K | 460 K | 558 K | 104 K | 1.92 M | 4.38 M | 2.19 M | 1.47 M | 2.03 M | 1.31 M | 1.15 M | 3.45 M | 4.88 M | 6.36 M |
Total Inventories |
106 M | 97.1 M | 82.7 M | 75.4 M | 71.7 M | 65.6 M | 78.5 M | 76 M | 84 M | 94 M | 89.1 M | 95.8 M | 100 M | 132 M | 129 M | 115 M | 89 M | 78.5 M | 86.4 M | 97.9 M | 84.4 M | 73.9 M | 75.2 M | 66.9 M | 77.4 M | 68.3 M | 56.3 M | 54.6 M | 40.6 M | 32 M | 24.1 M | 11.1 M | 24.1 M | 24.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Alnylam Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
USA
Schweiz
Canada
Israel
